Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

Details

Serval ID
serval:BIB_3B9C918EC585
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
Journal
Journal of Clinical Oncology
Author(s)
van Baren N., Bonnet M.C., Dréno B., Khammari A., Dorval T., Piperno-Neumann S., Liénard D., Speiser D., Marchand M., Brichard V.G., Escudier B., Négrier S., Dietrich P.Y., Maraninchi D., Osanto S., Meyer R.G., Ritter G., Moingeon P., Tartaglia J., van der Bruggen P., Coulie P.G., Boon T.
ISSN
0732-183X
Publication state
Published
Issued date
12/2005
Peer-reviewed
Oui
Volume
23
Number
35
Pages
9008-9021
Language
english
Abstract
PURPOSE: To evaluate the toxicity, antitumoral effectiveness, and immunogenicity of repeated vaccinations with ALVAC miniMAGE-1/3, a recombinant canarypox virus containing a minigene encoding antigenic peptides MAGE-3(168-176) and MAGE-1(161-169), which are presented by HLA-A1 and B35 on tumor cells and can be recognized by cytolytic T lymphocytes (CTLs). MATERIALS AND METHODS: The vaccination schedule comprised four sequential injections of the recombinant virus, followed by three booster vaccinations with the MAGE-3(168-176) and MAGE-1(161-169) peptides. The vaccines were administered, both intradermally and subcutaneously, at 3-week intervals. RESULTS: Forty patients with advanced cancer were treated, including 37 melanoma patients. The vaccines were generally well tolerated with moderate adverse events, consisting mainly of transient inflammatory reactions at the virus injection sites. Among the 30 melanoma patients assessable for tumor response, a partial response was observed in one patient, and disease stabilization in two others. The remaining patients had progressive disease. Among the patients with stable or progressive disease, five showed evidence of tumor regression. A CTL response against the MAGE-3 vaccine antigen was detected in three of four patients with tumor regression, and in only one of 11 patients without regression. CONCLUSION: Repeated vaccination with ALVAC miniMAGE-1/3 is associated with tumor regression and with a detectable CTL response in a minority of melanoma patients. There is a significant correlation between tumor regression and CTL response. The contribution of vaccine-induced CTL in the tumor regression process is discussed in view of the immunologic events that could be analyzed in detail in one patient.
Keywords
Adult, Aged, Aged, 80 and over, Antigens, Neoplasm/immunology, Canarypox virus/immunology, Cancer Vaccines/immunology, Disease Progression, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Melanoma/immunology, Melanoma/therapy, Middle Aged, Neoplasm Proteins/immunology, T-Lymphocytes, Cytotoxic/immunology, Treatment Outcome, Viral Vaccines/immunology
Pubmed
Web of science
Create date
28/01/2008 11:32
Last modification date
20/08/2019 13:31
Usage data